In this article, we will look at the Top 10 Undervalued Blue Chip Stocks Analysts Recommend for Smart Investing.
Jamie Dimon commented on May 29 at the Reagan National Economic Forum that the market is exuberant but not bad. He believes that the market is exuberant, and exuberance can last a long time, and it is overall not bad. Earnings are up 15-20% this year, and a lot of these companies have huge order books, so it may be justified. There is also hype in other avenues and commodities, and credit spreads are very low. He sees all of these factors as a risk, justifying that while they do make you feel good, if something goes wrong, those asset prices can come down.
READ ALSO: 10 Best Commodity Stocks to Buy for the Supercycle AND 12 Best Small Cap Tech Stocks to Buy According to Hedge Funds.
Dimon also stated that interest rates are a gravity to asset prices, and so it is indeed a risk, but not one he is terrified about. He believes whatever it is can be handled, looking at the risk and the range of potential outcomes. We recently talked about the factors driving record market moves in a recently published article on the 10 Best Momentum Stocks to Buy According to Analysts. Here is an excerpt from the article:
On May 22, Steve Sosnick, from Interactive Brokers, appeared on CNBC’s ‘Power Lunch’ to talk about what is driving the record market moves. Talking about why the market is going high despite the current market dynamics, he said that this is an everything rally, and one of the things that is a hallmark of it is not only the fact that the semis are up 70% in six weeks, which in itself is crazy enough, but rather about what he calls the ratchet effect of the peace dividend. The market is telling us today that they are more concerned about missing some sort of peace in the Middle East than they are about the risks of going home over a three-day weekend.
Sosnick also called for us to think about how we have reacted to any positive news, no matter how remote, about any sort of development in the Middle East that might bring a resolution to this situation. We all want that, but we go up when it is touted, and we do nothing when it doesn’t come out. That, to him, is the ratchet effect.
With these broad market trends in view, let’s look at the top 10 undervalued blue chip stocks analysts recommend for smart investing.
Our Methodology
We used the Finviz stock screener and online sources to identify the best blue chip stocks with a forward P/E below 15 and analyst consensus Moderate to Strong Buy ratings. We then selected the top 10 stocks most popular among hedge funds as of Q1 2026, using the hedge fund sentiment data from Insider Monkey’s database. The stocks are arranged in ascending order of hedge fund sentiment.
Note: All data was recorded on May 29.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
Top 10 Undervalued Blue Chip Stocks Analysts Recommend for Smart Investing
10.Toyota Motor Corporation (NYSE:TM)
Number of Hedge Fund Holders: 20
Toyota Motor Corporation (NYSE:TM) is one of the top 10 undervalued blue chip stocks analysts recommend for smart investing. Reuters reported on May 28 that, according to a report by Toyota Motor Corporation (NYSE:TM) released on Thursday, the company’s global vehicle sales dropped for a third consecutive month in April, hit primarily by sharp declines in the Middle East and China. It further clarified that global sales fell 3.1% from the prior year period to 849,306 vehicles, while overseas sales dropped 7.5%. However, sales in Japan grew 24.2%, rebounding after earlier purchase delays that took place ahead of an environmental tax change.
Reuters also provided a region-wise breakdown, reporting that sales in the Middle East fell 33.7% to just over 31,000 vehicles and dropped 25.4% in China in a backdrop featuring tough market conditions. Sales in the company’s biggest market, the United States, also dropped 4.6%.
Toyota Motor Corporation (NYSE:TM) further stated that global production grew 2.0% in April compared to the prior year period, with a 12.9% growth in Asia helping offset declines in the U.S. and Japan. The company’s figures include its luxury Lexus brand.
Toyota Motor Corporation (NYSE:TM) manufactures and sells motor vehicles and parts. The company’s operations are divided into the following segments: Automotive, Financial Services, and All Other.
9. Royal Bank of Canada (NYSE:RY)
Number of Hedge Fund Holders: 32
Royal Bank of Canada (NYSE:RY) is one of the top 10 undervalued blue chip stocks analysts recommend for smart investing. Barclays lifted the price target on Royal Bank of Canada (NYSE:RY) to C$260 from C$245 on May 29, maintaining an Overweight rating on the shares. The rating update came after the bank reported financial results for fiscal Q1 2026 on May 28, with the firm telling investors in a research note that Royal Bank of Canada’s (NYSE:RY) adjusted earnings beat expectations on better-than-anticipated fee income.
In its financial results for the quarter ended April 30, 2026, the company reported net income of $5.5 billion, up $1,119 million or 25% from the previous year. Diluted EPS rose 27% over the same period to $3.85, highlighting growth across each of Royal Bank of Canada’s (NYSE:RY) business segments. Adjusted net income and adjusted diluted EPS for the quarter were $5.6 billion and $3.90, up 23% and 25%, respectively, from the prior year.
Royal Bank of Canada (NYSE:RY) provides banking and financial services. The company’s operations are divided into the following segments: Personal and Commercial Banking, Wealth Management, Insurance, Capital Markets, and Corporate Support.
8. The Toronto-Dominion Bank (NYSE:TD)
Number of Hedge Fund Holders: 33
The Toronto-Dominion Bank (NYSE:TD) is one of the top 10 undervalued blue chip stocks analysts recommend for smart investing. Barclays lifted the price target on The Toronto-Dominion Bank (NYSE:TD) to C$140 from C$135 on May 29, maintaining an Underweight rating on the shares. The rating update came after the bank reported financial results for fiscal Q2 2026. The Toronto-Dominion Bank (NYSE:TD) also received a rating update from CIBC the same day, with the firm raising the price target on the stock to C$164 from C$151 and maintaining a Neutral rating on the shares.
In its financial results for the quarter ended April 30, 2026, The Toronto-Dominion Bank (NYSE:TD) announced that reported diluted earnings per share were $2.43, compared with $6.27 in the prior year period, while adjusted diluted earnings per share were $2.38, compared to $1.97 in fiscal Q2 2025. Reported net income for the quarter was $4,251 million, compared with $11,129 million, with the adjusted net income reaching $4,168 million, compared with $3,626 million in the prior year period.
The Toronto-Dominion Bank (NYSE:TD) provides financial products and services. Its operations are divided into the following segments: Canadian Personal and Commercial Banking, U.S. Retail, Wealth Management and Insurance, Wholesale Banking, and Corporate segment.
7. T-Mobile US, Inc. (NASDAQ:TMUS)
Number of Hedge Fund Holders: 85
T-Mobile US, Inc. (NASDAQ:TMUS) is one of the top 10 undervalued blue chip stocks analysts recommend for smart investing. T-Mobile US, Inc. (NASDAQ:TMUS) announced on May 28 a multi-year partnership with the United States Golf Association (USGA), making the company the Official 5G Network Partner of the U.S. Women’s Open, U.S. Open, and additional USGA championships. Management stated that through the partnership, T-Mobile US, Inc. (NASDAQ:TMUS) is delivering the USGA’s first-ever mobile Rules Review, critical event connectivity, and exclusive member experiences.
Separately, T-Mobile US, Inc. (NASDAQ:TMUS) received several rating updates following the release of its financial results for Q1 on April 28. Scotiabank cut the price target on the stock to $263 from $266 on April 29, reiterating an Outperform rating on the shares and telling investors that it believes the company has responded well to increased promotional intensity.
T-Mobile US, Inc. (NASDAQ:TMUS) also received a rating update from BofA the same day. The firm lowered the price target on the stock to $220 from $270, maintaining a Neutral rating on the shares and stating that the company “wrapped up the theme of rational competition and lower device subsidies” for wireless carriers in Q1.
T-Mobile US, Inc. (NASDAQ:TMUS) provides wireless communications services under the T-Mobile and MetroPCS brands. The company offers prepaid and postpaid wireless messaging, voice, and data services, along with wholesale wireless services.
6. AbbVie Inc. (NYSE:ABBV)
Number of Hedge Fund Holders: 87
AbbVie Inc. (NYSE:ABBV) is one of the top 10 undervalued blue chip stocks analysts recommend for smart investing. AbbVie Inc. (NYSE:ABBV) announced on May 29 authorization by the European Commission (EC) for an expanded label for VENCLYXTO® to include use in combination with acalabrutinib (with or without obinutuzumab), along with use in combination with ibrutinib to treat adult patients with previously untreated chronic lymphocytic leukemia (CLL). Management stated that the expanded label follows the EC’s inclusion of these combinations in the acalabrutinib and ibrutinib labels, with all-oral, fixed-duration combination regimens supporting the current standards of care. It added that they can also offer providers and patients additional targeted oral medications for CLL in the first-line setting that include the potential for time off treatment.
AbbVie Inc. (NYSE:ABBV) further clarified that the European Commission authorization extends to all European Union Member States, and includes Iceland, Norway, and Liechtenstein. Svetlana Kobina, MD, PhD, vice president, global medical affairs, oncology, AbbVie, stated that the VENCLYXTO-based combination regimens exhibited “a favorable efficacy and safety profile in the first-line setting for chronic lymphocytic leukemia”.
AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.
While we acknowledge the potential of ABBV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABBV and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the Top 5 Undervalued Blue Chip Stocks Analysts Recommend for Smart Investing.
Disclosure: None. Follow Insider Monkey on Google News.
